Posted by Rosy Crucifiction on February 23, 2010, at 21:13:19
In reply to Re: betahistine for cognitive dysfunction (safety, posted by psychobot5000 on October 2, 2009, at 0:49:20
There is some very interesting work out about this now. There is a clinical trial of Betahistine at U of Cincinnati for Atypical Depression. A long and illuminating article discusses the the apparent functioning. Abstract here, link to full article below. FYI, the medication is available by prescription in Europe and Canada. It is inexpensive.
"Histamine H3 Receptor Antagonists: Preclinical Promise for Treating Obesity and Cognitive Disorders1. Timothy A. Esbenshade,
2. Gerard B. Fox and
3. Marlon D. Cowart+ Author Affiliations
1.
Division of Neuroscience Research, Global Pharmaceutical Research and Development, 100 Abbott Park Road, Abbott Park, IL 60064
Next Section
AbstractThe histamine H3 receptor is an attractive G proteincoupled receptor drug target that regulates neurotransmission in the central nervous system and plays a role in cognitive and homeostatic functions. Drug discovery efforts by numerous pharmaceutical companies have focused on the preclinical development of H3 receptor antagonists for the potential treatment of attention-deficit hyperactivity disorder, dementias, schizophrenia, as well as obesity and sleep disorders. This receptor exhibits molecular, pharmacological, and functional heterogeneity that informs the preclinical development of effective antagonists. Herein, we describe the biological and chemical implications for developing H3 receptor antagonists and their therapeutic potential as disclosed through animal models of cognition, sleep, and obesity.
Previous SectionNext SectionGraphic
Since the original description of the histamine H3 receptor as a presynaptic autoreceptor that inhibits histamine release, there has been considerable effort to develop potent and selective H3 receptor antagonists for the potential treatment of a variety of disorders affecting cognition (Attention Deficit Hyperactivity Disorder, Alzheimer Disease, and schizophrenia), sleep (hypersomnia and narcolepsy), and homeostasis (obesity). We review some of the preclinical considerations, from both an H3 receptor biology as well as a more general drug discovery perspective, that need to be taken into account in developing effective H3 receptor antagonists for the treatment of these diseases."
poster:Rosy Crucifiction
thread:919307
URL: http://www.dr-bob.org/babble/20100216/msgs/937779.html